Moreover, there are numerous cancers with downregulation of extracellular Wnt inhibitors such as DKK1, sFRP and Wif1 that make the development of therapies targeting the Wnt ligand-receptor complex low hanging fruit [100,101,102]. The gene discussed is WIF1; the disease is cancer.